Valuation: Quest PharmaTech Inc.

Market Cap 4.23M 3.01M 2.63M 2.43M 2.25M 289M 4.3M 28.98M 11.37M 141M 11.3M 11.05M 487M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 5.21M 3.71M 3.24M 3M 2.77M 356M 5.31M 35.74M 14.02M 174M 13.93M 13.63M 601M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
1 day+25.00%
1 month-28.57%
3 months-16.67%
6 months-28.57%
Current year-28.57%
1 week 0.02
Extreme 0.02
0.02
1 month 0.02
Extreme 0.02
0.04
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.1
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Date Insider Type Main position Quantity % Market Cap.
12-12OtherCompany 0 0%
21/10/25Other

Chief Executive Officer

700,000 0.4139%
21/10/25Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
+25.00%0.00%-28.57%-73.68% 3.01M
-0.27%+1.36%+3.05%+7.32% 50.35B
-1.01%-3.41%+384.77%+588.80% 39.32B
+0.77%+2.77%+32.82%-5.39% 34.69B
+2.27%+3.71%+16.08%+58.20% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
-0.35%-4.37% - - 16.49B
-0.91%+0.21%+70.48%+115.52% 15.31B
+0.43%+3.34%+14.96%+17.98% 13.8B
+0.54%+2.24%+16.20%-30.96% 12.87B
Average +2.82%-0.36%+57.11%+78.35% 24.35B
Weighted average by Cap. +0.37%-0.32%+81.82%+121.85%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.28M -1.12M -1.04M -956K -123M -1.83M -12.35M -4.84M -60.27M -4.81M -4.71M -208M 5M 3.56M 3.11M 2.87M 2.65M 342M 5.09M 34.26M 13.44M 167M 13.36M 13.06M 576M
Net Debt 795K 566K 494K 457K 422K 54.32M 809K 5.45M 2.14M 26.6M 2.12M 2.08M 91.59M 986K 701K 613K 567K 523K 67.36M 1M 6.76M 2.65M 32.98M 2.63M 2.58M 114M
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
14/07/26 CA$0.0250 +25.00% 19,600
10/07/26 CA$0.0200 -20.00% 155,100
09/07/26 CA$0.0250 0.00% 1,600